Ikena Oncology (IKNA) Competitors $1.12 +0.01 (+0.90%) As of 04/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IKNA vs. YMAB, SLRN, IMMP, PROK, HUMA, ITOS, SLDB, CRVS, CRGX, and CDTXShould you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Y-mAbs Therapeutics (YMAB), Acelyrin (SLRN), Immutep (IMMP), ProKidney (PROK), Humacyte (HUMA), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), Corvus Pharmaceuticals (CRVS), CARGO Therapeutics (CRGX), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. Ikena Oncology vs. Y-mAbs Therapeutics Acelyrin Immutep ProKidney Humacyte iTeos Therapeutics Solid Biosciences Corvus Pharmaceuticals CARGO Therapeutics Cidara Therapeutics Y-mAbs Therapeutics (NASDAQ:YMAB) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk, community ranking and dividends. Do analysts rate YMAB or IKNA? Y-mAbs Therapeutics currently has a consensus target price of $18.30, indicating a potential upside of 290.19%. Ikena Oncology has a consensus target price of $3.00, indicating a potential upside of 170.27%. Given Y-mAbs Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Y-mAbs Therapeutics is more favorable than Ikena Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Y-mAbs Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91Ikena Oncology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to YMAB or IKNA? In the previous week, Y-mAbs Therapeutics had 2 more articles in the media than Ikena Oncology. MarketBeat recorded 3 mentions for Y-mAbs Therapeutics and 1 mentions for Ikena Oncology. Ikena Oncology's average media sentiment score of 1.00 beat Y-mAbs Therapeutics' score of 0.44 indicating that Ikena Oncology is being referred to more favorably in the news media. Company Overall Sentiment Y-mAbs Therapeutics Neutral Ikena Oncology Positive Which has better valuation and earnings, YMAB or IKNA? Y-mAbs Therapeutics has higher revenue and earnings than Ikena Oncology. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Ikena Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioY-mAbs Therapeutics$87.69M2.42-$21.43M-$0.67-7.00Ikena Oncology$659K81.28-$68.17M-$1.01-1.10 Does the MarketBeat Community favor YMAB or IKNA? Y-mAbs Therapeutics received 108 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 63.30% of users gave Y-mAbs Therapeutics an outperform vote while only 58.82% of users gave Ikena Oncology an outperform vote. CompanyUnderperformOutperformY-mAbs TherapeuticsOutperform Votes13863.30% Underperform Votes8036.70% Ikena OncologyOutperform Votes3058.82% Underperform Votes2141.18% Which has more risk and volatility, YMAB or IKNA? Y-mAbs Therapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Ikena Oncology has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Is YMAB or IKNA more profitable? Ikena Oncology has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -28.22%. Y-mAbs Therapeutics' return on equity of -24.61% beat Ikena Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Y-mAbs Therapeutics-28.22% -24.61% -18.49% Ikena Oncology N/A -36.88%-33.08% Do insiders & institutionals hold more shares of YMAB or IKNA? 70.8% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are held by institutional investors. 22.5% of Y-mAbs Therapeutics shares are held by insiders. Comparatively, 5.9% of Ikena Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryY-mAbs Therapeutics beats Ikena Oncology on 14 of the 19 factors compared between the two stocks. Get Ikena Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKNA vs. The Competition Export to ExcelMetricIkena OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.57M$2.84B$5.30B$7.35BDividend YieldN/A1.86%5.12%4.30%P/E Ratio-0.9030.4821.8017.80Price / Sales81.28441.91379.9697.74Price / CashN/A168.6838.2634.64Price / Book0.323.466.443.98Net Income-$68.17M-$72.06M$3.21B$247.73M7 Day Performance0.91%2.58%2.87%1.81%1 Month Performance-13.28%-15.68%-8.63%-6.98%1 Year Performance-11.90%-26.09%11.46%1.37% Ikena Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKNAIkena Oncology3.0862 of 5 stars$1.11flat$3.00+170.3%-10.5%$53.57M$659,000.00-0.9070Short Interest ↓News CoveragePositive NewsYMABY-mAbs Therapeutics3.5162 of 5 stars$4.93+2.1%$18.30+271.2%-69.0%$222.93M$87.69M-9.13150Short Interest ↓Positive NewsSLRNAcelyrin3.5426 of 5 stars$2.18-2.2%$9.60+340.4%-56.2%$219.98MN/A-0.89135Short Interest ↓Positive NewsIMMPImmutep1.1009 of 5 stars$1.49+2.1%$8.50+470.5%-31.9%$216.88M$5.14M0.002,021Positive NewsPROKProKidney2.4525 of 5 stars$0.74+1.2%$5.00+575.7%-72.2%$216.60M$76,000.00-1.353Insider TradeNews CoveragePositive NewsGap UpHUMAHumacyte2.5518 of 5 stars$1.49-2.6%$13.71+820.4%-46.2%$215.82M$1.57M-1.11150Positive NewsGap UpITOSiTeos Therapeutics2.2491 of 5 stars$5.53-2.1%$25.75+365.6%-39.0%$211.21M$35M-1.7690Short Interest ↑SLDBSolid Biosciences3.3487 of 5 stars$2.71+0.4%$15.67+478.1%-74.5%$210.01M$8.09M-0.89100CRVSCorvus Pharmaceuticals2.4673 of 5 stars$3.03+1.7%$15.67+417.1%+138.2%$206.45MN/A-3.2630Gap DownCRGXCARGO Therapeutics2.6164 of 5 stars$4.46+4.7%$15.00+236.3%-76.2%$205.39MN/A-1.05116CDTXCidara Therapeutics4.0611 of 5 stars$18.74+3.0%$39.14+108.9%+34.6%$205.26M$1.28M-0.7390Analyst UpgradeShort Interest ↑ Related Companies and Tools Related Companies YMAB Competitors SLRN Competitors IMMP Competitors PROK Competitors HUMA Competitors ITOS Competitors SLDB Competitors CRVS Competitors CRGX Competitors CDTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IKNA) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ikena Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
